Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21748845 | 0.86 | POLB (0.43) | POLBGPR119GRM5DTYMKDDB1 | |
| SCHEMBL21748843 | 0.86 | POLB (0.43) | POLBGPR119GRM5DTYMKDDB1 | |
| SCHEMBL30783231 | 0.86 | POLB (0.43) | POLBGPR119GRM5DTYMKDDB1 | |
| SCHEMBL30783165 | 0.85 | GPR119 (0.43) | GPR119GRM5DDB1CRBNGRM1 | |
| SCHEMBL5161957 | 0.85 | GPR119 (0.43) | GPR119GRM5DDB1CRBNGRM1 | |
| SCHEMBL5156856 | 0.82 | GPR119 (0.50) | POLBGPR119GRM5DTYMKGRM1 | |
| SCHEMBL30783224 | 0.80 | JAK2 (0.52) | POLBGPR119 | |
| SCHEMBL21748693 | 0.79 | GPR119 (0.50) | POLBGPR119USP30GCK | |
| SCHEMBL2248490 | 0.79 | DDB1 (0.41) | GPR119DDB1CRBNMAPTUSP30 | |
| SCHEMBL21775442 | 0.79 | GPR119 (0.50) | POLBGPR119USP30GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| CN-112236423-A | Piperidinyl-3- (aryloxy) propanamides and propionates | 武田药品工业株式会社 | 2021-01-15 | — | — | CN | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | POLB 3782/4885GPR119 31/4885GRM5 1082/4885 |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | POLB 3782/4885GPR119 31/4885GRM5 1082/4885 |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | POLB 3782/4885GPR119 31/4885GRM5 1082/4885 |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | POLB 3782/4885GPR119 31/4885GRM5 1082/4885 |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | POLB 3782/4885GPR119 31/4885GRM5 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.